AI brief
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind to build AI agents for drug development.
Why it matters: The combined effort aims to help pharma teams coordinate drug development tasks such as tracking trials and spotting problems.
Written by AI from The Decoder's published text.
Background
From our own funding, model and news trackers, not from the source.
OpenAI
- Latest funding
- $30B · 31 Oct 2026
- Newest model on the API
- GPT-6.1 Terra Pro · 26 Oct 2026 · $1 in / $5 out per million tokens
Source
“OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems.”
Reporting from a publisher outside the organisation being covered.
Read original story ↗